Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (3): 42-48.doi: 10.6040/j.issn.1671-7554.0.2018.708

Previous Articles    

Effect of gene mutation on the clinical efficacy of decitabine for patients with myelodysplastic syndrome

DOU Chunhui1, SHAO Jianhua1, DONG Xuebin1, ZHANG Ling2, CHEN Ping1, ZHAO Hongyu1, GU Linping1, SUN Lin1, XIE Jie1, WANG Min1, WANG Juan1, LI Na1, LI Fan1, LI Daqi1   

  1. 1. Department of Hematology, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, Shandong, China;
    2. Department of Gastroenterology, Yidu Central Hospital of Weifang, Qingzhou 262500, Shandong China
  • Published:2022-09-27

PDF (PC)

3

Abstract: Objective To investigate the effect of gene mutation and related clinical indicators on the prognosis of patients with myelodysplastic syndromes(MDS). Methods Clinical data of 38 MDS patients were collected. Clinical specimens such as blood and genetic sequencing and karyotype analysis of bone marrow fluid were also collected. The response rate and survival rate of MDS patients treated with decitabine were statistically analyzed by single factor and multiple factors using SPSS software. The effects of clinical features and gene mutation on the prognosis of MDS patients treated with decitabine were retrospectively analyzed. Results Among the 38 cases, 92% of patients had at 山 东 大 学 学 报 (医 学 版)57卷3期 -窦春慧,等.骨髓增生异常综合征患者基因突变对地西他滨临床疗效的影响 \=-least one mutant gene and the detection rate of chromosome abnormality was 52.6%. Patients accepted monotherapy of decitabine or combined treatment with decitabine. The median number of treatment cycles was 4, and the total response rate was 63%(24/38). Fourteen patients were invalid. Multifactor analysis found that the response rate of patients with TET2 gene mutation was higher than those without mutation(82% vs 48%, Ps=0.043, Pm=0.034). The follow-up patients ended up with 12 deaths(32%). Median survival time of all patients was 27.6 months. Multifactor survival analysis found that chromosome karyotypes were good, intermediate and poor in 38 MDS patients and their survival time were 31.4, 17.6, 10.4 months, respectively. The risk stratification of IPSS were low risk, intermediate-1, intermediate-2, high risk and median survival time were 31.4, 27.6, 23.4, 11.4 months, respectively. Median survival time for patients with hemoglobin ≥100 g/L and <100 g/L were respective 31.4 and 19.4 months. Median survival time for patients with the number of cytopenias with 0-1 and greater than 2 were respective 31.4 and 17.6 months. The indicators mentioned above were statistically different(all P<0.05). Median survival time of patients with and without TP53 mutation were 16.4 and 31.4 months without statistical difference(P=0.097). Conclusion Patients with TET2 gene mutation have higher response rate to chemotherapy than those without mutation.

Key words: Myelodysplastic syndromes, Decitabine, Gene mutation, Prognosis

CLC Number: 

  • R551.3
[1] Nimer SD. Myelodysplastic syndromes[J]. Blood, 2008, 111(10): 4841-4851.
[2] Nolte F, Hofmann WK. Molecular mechanisms involved in the progression of myelodysplastic syndrome[J]. Future Oncol, 2010, 6(3): 445-455.
[3] Figueroa ME, Skrabanek L, Li YS, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation[J]. Blood, 2009, 114(16): 3448-3458.
[4] Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study[J]. Cancer, 2006, 106(8): 1794-1803.
[5] Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study[J]. Lancet Oncol, 2009, 10(3): 223-232.
[6] 宋慧慧, 陈宝安, 刘苒, 等. 地西他滨3 d方案治疗骨髓增生异常综合征疗效讨论附两例病例报道[J]. 东南大学学报(医学版), 2011, 30(3): 474-477. SONG Huihui, CHEN Baoan, LIU Ran, et al. Discussion of decitabine 3-day program treatment on myelodysplastic syndrome-report of 2 cases[J]. Journal of Southeast University(Medical Science Edition), 2011, 30(3): 474-477.
[7] 高冲,陈宝安,刘苒,等.地西他滨治疗骨髓增生异常综合征一例报告[J]. 现代医学, 2010, 38(2): 189-190. GAO Chong, CHEN Baoan, LIU Ran, et al. A case report of decitabine treatment of myelodysplastic syndrome[J]. Modern Medical Journal, 2010, 38(2): 189-190.
[8] Fenaux P, Ades L. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes[J]. Leuk Res, 2009, 33(Suppl 2): S7-11.
[9] Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization(WHO)classification of myeloid neoplasms and acute leukemia: rationale and important changes[J]. Blood, 2009, 114(5): 937-951.
[10] Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J]. Blood, 2016, 127(20): 2391-2405.
[11] Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group(IWG)response criteria in myelodysplasia[J]. Blood, 2006, 108(2): 419-425.
[12] Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes[J]. Blood, 1997, 89(6): 2079-2088.
[13] Wu H, Zhang Y. Reversing DNA methylation: mechanisms, genomics, and biological functions[J]. Cell, 2014, 156(1/2): 45-68.
[14] Traina F, Visconte V, Elson P, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms[J]. Leukemia, 2014, 28(1): 78-87.
[15] Matsuda A, Germing U, Jinnai I, et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes[J]. Blood, 2005, 106(8): 2633-2640.
[16] Adès L, Itzykson R, Fenaux P. Myelodysplastic syndromes[J]. The Lancet, 2014, 383(9936): 2239-2252.
[17] Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias[J]. Leukemia, 2011, 25(7): 1147-1152.
[18] Braun T, Itzykson R, Renneville A, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial[J]. Blood, 2011, 118(14): 3824-3831.
[19] Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients[J]. Blood, 2014, 124(17): 2705-2712.
[20] Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes [J]. N Engl J Med, 2016, 375(21): 2023-2036.
[21] Zhao YS, Guo J, Xu F, et al. Predict response to decitabine in patients with myelodysplastic syndrome and related neoplasms [J]. Zhonghua Xue Ye Xue Za Zhi, 2017, 38(2): 124-128.
[22] Chang CK, Zhao YS, Xu F, et al. TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes[J]. Br J Haematol, 2017, 176(4): 600-608.
[23] Im AP, Sehgal AR, Carroll MP, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies[J]. Leukemia, 2014, 28(9): 1774-1783.
[24] Thol F, Friesen I, Damm F, et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes[J]. J Clin Oncol, 2011, 29(18): 2499-2506.
[25] Gelsi-Boyer V, Trouplin V, Adélaïde J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia[J]. Br J Haematol, 2009, 145(6): 788-800.
[26] Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes[J]. N Engl J Med, 2011, 364(26): 2496-2506.
[27] Itzykson R, Thépot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine[J]. Blood, 2011, 117(2): 403-411.
[28] Zeidan AM, Lee JW, Prebet T, et al. Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes[J]. Br J Haematol, 2014, 166(3): 352-359.
[29] Breccia M, Loglisci G, Cannella L, et al. Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response[J]. Leuk Lymphoma, 2012, 53(5): 985-986.
[30] Ye L, Ren YL, Xie LL, et al. A preliminary study on the outcome of lower-risk myelodysplastic syndrome by low-dose decitabine[J]. Zhonghua Xue Ye Xue Za Zhi, 2017, 38(4): 307-312.
[31] Hong JY, Seo JY, Kim SH, et al. Mutations in the spliceosomal machinery genes SRSF2, U2AF1, and ZRSR2 and response to decitabine in myelodysplastic syndrome[J]. Anticancer Res, 2015, 35(5): 3081-3089.
[1] ZHENG Su, CHEN Shuhua, LI Hua, DENG Jie, CHEN Chunhong, WANG Xiaohui, FENG Weixing, HAN Xiaodi, ZHANG Yujia, LI Na, LI Mo, FANG Fang. Correlation between EEG variations and BASED evaluation of the efficacy of ACTH treatment in 54 cases of infantile spasms [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 91-96.
[2] WANG Lihui, GAO Min, KONG Beihua. Angiosarcoma of the uterus: a report of 2 cases and literature review [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 108-112.
[3] HE Shiqing, LI Wanwan, DONG Shuqing, MOU Jingyi, LIU Yuying, WEI Siyu, LIU Zhao, ZHANG Jiaxin. Construction of a prognostic risk model of pyroptosis-related genes in breast cancer based on database [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 34-43.
[4] ZHANG Yufeng, XU Min, XING Xiuli, PANG Shuguang, HU Keqing. Epidemiological characteristics of 689 patients with non-ST-segment elevation myocardial infarction [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 118-122.
[5] LI Linlin, WANG Kai. Prediction of hepatocellular carcinoma prognostic genes based on bioinformatics [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 50-58.
[6] PAN Pengfei, XU Lisheng, JI Kunqian, WANG Dexiang, LI Yu. Mitochondrial myopathy beginning with respiratory failure: one case and literature review [J]. Journal of Shandong University (Health Sciences), 2022, 60(2): 54-59.
[7] Benkang SHI,Shouzhen CHEN,Sifeng QU,Yong WANG,Lei LIU. Research progress and clinical characteristics of clinical rapidly progressing prostate cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 110-116.
[8] CHU Yan, LIU Duanrui, ZHU Wenshuai, FAN Rong, MA Xiaoli, WANG Yunshan, JIA Yanfei. Expressions of DNA methyltransferases in gastric cancer and their clinical significance [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 1-9.
[9] CHEN Liyu, XIAO Juan, LYU Xianzhong, DUAN Baomin, HONG Fanzhen. Risk factors influencing prognosis of lower extremity deep vein thrombosis in pregnant and parturient women [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 38-42.
[10] TIAN Yaotian, WANG Bao, LI Yeqin, WANG Teng, TIAN Liwen, HAN Bo, WANG Cuiyan. Machine learning models based on interpretive CMR parameters can predict the prognosis of pediatric myocarditis [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 43-49.
[11] LI Wanwan, ZHOU Wenkai, DONG Shuqing, HE Shiqing, LIU Zhao, ZHANG Jiaxin, LIU Bin. Construct of a risk assessment model of breast cancer immune-related lncRNAs based on the database information [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 74-84.
[12] MI Qi, SHI Shuang, LI Juan, LI Peilong, DU Lutao, WANG Chuanxin. Construction of circRNA-mediated ceRNA network and prognostic assessment model for bladder cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 94-102.
[13] SUN Yu, CHEN Na, MA Aihua. A case of congenital disorder of glycosylation caused by SLC35A2 gene mutation [J]. Journal of Shandong University (Health Sciences), 2021, 59(4): 113-116.
[14] HUANG Xiuli, LIU Bingju, SUN Lifeng. Activated phosphoinositide 3-kinase δ syndrome caused by a mutation in PIK3CD gene: a case report and literature review [J]. Journal of Shandong University (Health Sciences), 2021, 59(3): 107-112.
[15] LI Xiangqing, YIN Xin, ZHAO Xuelian, ZHAO Peiqing. Expression and clinical significance of circulating CD56bright subset of NK cells in patients with Parkinsons disease [J]. Journal of Shandong University (Health Sciences), 2021, 59(2): 34-40.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd